早期息护理与多发性骨髓瘤的通常血液护理:回顾性队列研究
Davide Giusti1, Elisabetta Colaci1, Valeria Pioli1
1Hematology Unit and Chair, Azienda Ospedaliera Universitaria di Modena and Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
BMJ supportive & palliative care
|September 26, 2023
概括
早期息治疗 (EPC) 显著改善了多发性骨髓瘤 (MM) 患者的护理质量和疼痛管理. 将EPC整合到常规实践中可以改善终身护理,而不会影响生存率.
科学领域:
- 血液学 血液学 血液学
- 抚慰性护理是一种缓解性护理.
- 在瘤学瘤学.
背景情况:
- 早期缓解性护理 (EPC) 已被确认为对急性髓性白血病有益.
- 在多发性骨髓瘤 (MM) 中EPC的价值仍然不太了解.
- 本研究调查了EPC对MM患者息和终身护理 (EOL) 质量的影响.
研究的目的:
- 为了比较MM患者接受EPC与通常的血液治疗 (UHC) 的缓解和EOL护理的质量指标.
- 评估EPC对疼痛管理和EOL护理积极性的影响.
- 为了评估MM患者的生存结果,有和没有EPC.
主要方法:
- 对290名MM患者进行了回顾性观察性研究.
- 抽象的质量指标包括心理支持,疼痛管理,护理目标讨论,提前护理计划,家庭护理准入和EOL治疗的攻击性.
- 统计比较使用未调整和混调整的回归模型.
主要成果:
- 与UHC患者 (n=231) 相比,接受EPC的患者 (n=55) 的质量指标数量显著增加 (平均值为2.62对1.12,p<0.0001).
- 随着时间的推移,EPC与疼痛强度的显著减少有关 (p<0.01).
- 观察到EOL护理攻击性减少的趋势,生存率没有显著差异 (5.3年与5.46年,p=0.74).
结论:
- 这些发现支持将EPC整合到常规MM护理中.
- EPC提高了MM患者的息和EOL护理的质量.
- 需要进一步的前性研究来证实这些结果.
相关概念视频
Continuing Care
1.5K
Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
1.5K
Cancer Survival Analysis
380
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
380
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Bone Marrow Sampling and Transplants
352
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
352
Kaplan-Meier Approach
178
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
178
Comparing the Survival Analysis of Two or More Groups
218
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
218


